Overview

Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
In this randomized, double-blind, placebo-controlled, multicentre trial, 126 patients between July 5, 2007 and July 30, 2008 were enrolled from 10 centers. The leader units are Shanghai Chest Hospital Affiliated to Shanghai Jiao-Tong University and Shanghai Changzheng Hospital. All eligible patients received 1 cycle (21 days) of TC chemotherapy. After chemotherapy, patients evaluated as SD (Stable Disease) or above were randomized to receive endostar plus TC or TC alone for 3 cycles, 21 days as one cycle.
Phase:
Phase 2
Details
Lead Sponsor:
Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Endostar protein
Endostatins
Paclitaxel